MSTN and type 2 diabetes mellitus: No differences in the muscle expression of the myostatin-inhibitory factor SMAD7 or the myogenic factors MEF2C, MYOG, MYF5, and MYF6 were found between groups, except for a tendency toward a reduced expression of MYOD1 (p = 0.064) in patients with T2D.